4.85
-2.02%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About SenzaGen
Its shares trade on Nasdaq Stockholm under the ticker SENZA.ST. It has been listed since 21 September 2017. In the fiscal year to 31 December 2025, it reported revenue of SEK 58.0m and a net loss of SEK 11.6m. At that date it held total assets of SEK 116.1m and shareholders' equity of SEK 77.7m.
SenzaGen AB engages in the development of in vitro test methods for prediction of chemical and protein sensitizers. The company is headquartered in Lund, Skane. The company went IPO on 2017-09-21. The firm markets, sells and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its own laboratory and through licensed Contract Research Organization (CROs). SenzaGen AB makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals people come in contact with in their daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The firm sells the tests in Sweden and the United States, and also sells through partners in several other countries. SenzaGen AB has a subsidiary in San Francisco, the United States.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 21 Sept 2017
- Employees
- 16
- Website
- senzagen.com ↗
Leadership
Pay as last reported
- Prof. Carl BorrebaeckChairman of the Board, since 2010SEK 200,000
- Mr. Peter NahlstedtChief Executive Officer, since 2018SEK 67,000
- Mr. Henrik JohanssonChief Scientific Officer
- Ms. Marianne OlssonVice President - Finance, since 2016
- Ms. Maria AgemarkVice President - Operations, since 2015
- Ms. Tina Dackemark LawessonVice President Marketing and Communications
- Ms. Anna Cherouvrier HanssonVice President - Business Development, since 2017
- Mr. Mikael WahlgrenChief Legal Officer, since 2019
- Dr. Anki Malmborg HagerDirectorSEK 966,000
- Prof. Ian KimberIndependent DirectorSEK 100,000
- Dr. Paul YianniIndependent Director
- Ms. Paula ZeilonIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- SenzaGen AB has a strong scientific background, with expertise in genomics and toxicology.
- The company has developed GARD®, a cutting-edge in vitro testing method that provides accurate and reliable results in identifying allergens.
- SenzaGen AB has a dedicated team of researchers and scientists who continuously work on improving and expanding their product portfolio.
Weaknesses
- Being a relatively small company, SenzaGen AB may face challenges in terms of limited resources and financial constraints compared to larger competitors.
- The market for alternative animal testing methods is highly competitive, and SenzaGen AB needs to ensure that their products and services stand out to attract customers.
- As a specialized company focusing on allergen testing, SenzaGen AB might face limitations in catering to a broader range of toxicological testing needs.
Opportunities
- Increasing regulatory pressure to reduce animal testing worldwide presents a significant opportunity for SenzaGen AB to market their alternative testing methods.
- Growing awareness among consumers regarding animal welfare and the demand for cruelty-free products can drive the demand for SenzaGen AB's testing services.
- Expanding their market presence globally can open doors for collaboration with international regulatory bodies, research institutions, and industry partners.
Threats
- The possibility of stricter regulations or new testing methods emerging in the future may impact the demand for SenzaGen AB's current product offerings.
- Competition from established players in the toxicology and genomics industry can pose a threat to SenzaGen AB's market share.
- Limited financial resources might hinder the company's ability to invest in research and development, impeding their innovation and competitiveness.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.